Win For Barr In Glaucoma Drug IP Suit Upheld By Fed. Circ.
Alcon claimed that Barr's abbreviated new drug application for a generic version of the drug would infringe its patents, but the appeals court concluded that the company did not prove infringement.
"We affirm the district court's holding that Alcon failed to prove by a preponderance of...
To view the full article, register now.